EGFR and lung cancer: NSCLC with sensitive epidermal growth factor receptor (EGFR) mutations may be susceptible to treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs), a breakthrough in lung cancer treatment this century that has opened a new chapter in the targeted therapy of solid tumors.